Introduction:
The pharmaceutical industry in Brazil has been experiencing significant growth in recent years, with the demand for biologics steadily increasing. In 2020, the biologics market in Brazil was valued at $2.5 billion, and it is expected to reach $4.3 billion by 2026. This market report will highlight the top 10 biologics manufacturers in Brazil in 2026.
Top 10 Biologics Manufacturers in Brazil 2026:
1. Novartis Brazil
Novartis Brazil is a leading biologics manufacturer in the country, with a market share of 15%. The company specializes in producing biologic drugs for various therapeutic areas, including oncology and immunology. Novartis Brazil has seen a 10% increase in production volume over the past year.
2. Roche Brazil
Roche Brazil is another key player in the Brazilian biologics market, holding a 12% market share. The company’s biologics portfolio includes treatments for cancer, autoimmune diseases, and infectious diseases. Roche Brazil has experienced a 5% growth in exports of biologic drugs.
3. AbbVie Brazil
AbbVie Brazil is known for its innovative biologics for the treatment of chronic diseases such as rheumatoid arthritis and psoriasis. The company has a 9% market share in Brazil and has seen a 7% increase in production volume.
4. Pfizer Brazil
Pfizer Brazil is a global pharmaceutical giant with a strong presence in the Brazilian biologics market. The company’s biologics division focuses on developing treatments for rare diseases and genetic disorders. Pfizer Brazil has a 8% market share and has doubled its exports of biologic drugs.
5. Sanofi Brazil
Sanofi Brazil is a key player in the Brazilian biologics market, with a 7% market share. The company’s biologics portfolio includes treatments for diabetes, cardiovascular diseases, and rare genetic disorders. Sanofi Brazil has seen a 6% increase in production volume.
6. AstraZeneca Brazil
AstraZeneca Brazil is a leading biologics manufacturer in the country, with a 6% market share. The company’s biologics division focuses on developing treatments for respiratory diseases, oncology, and autoimmune disorders. AstraZeneca Brazil has experienced a 4% growth in exports of biologic drugs.
7. Merck Brazil
Merck Brazil is known for its innovative biologics for the treatment of cancer, diabetes, and infectious diseases. The company has a 5% market share in Brazil and has seen a 3% increase in production volume.
8. Johnson & Johnson Brazil
Johnson & Johnson Brazil is a global pharmaceutical company with a strong presence in the Brazilian biologics market. The company’s biologics division focuses on developing treatments for rare diseases and genetic disorders. Johnson & Johnson Brazil has a 4% market share and has doubled its exports of biologic drugs.
9. Biogen Brazil
Biogen Brazil is a key player in the Brazilian biologics market, with a 3% market share. The company’s biologics portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. Biogen Brazil has seen a 2% increase in production volume.
10. Bristol Myers Squibb Brazil
Bristol Myers Squibb Brazil is a leading biologics manufacturer in the country, with a 2% market share. The company’s biologics division focuses on developing treatments for cancer, autoimmune diseases, and infectious diseases. Bristol Myers Squibb Brazil has experienced a 1% growth in exports of biologic drugs.
Insights:
The Brazilian biologics market is expected to continue its growth trajectory in the coming years, driven by increasing demand for innovative biologic treatments. By 2026, the market is projected to reach $4.3 billion, reflecting a CAGR of 6.8% from 2020. Key trends shaping the market include the rising prevalence of chronic diseases, advancements in biologic drug development, and increasing healthcare expenditure in Brazil. To stay competitive, biologics manufacturers in Brazil need to focus on expanding their product portfolios, strengthening their R&D capabilities, and enhancing their market access strategies.
Related Analysis: View Previous Industry Report
